Semaglutide is a research-grade compound supplied for laboratory use only.
Semaglutide
$89.99
Size / Strength
Every batch of Semaglutide is independently third-party tested. 30-day money-back guarantee — no questions asked.
Semaglutide – Research Overview
This product is intended solely for laboratory research purposes. Not for human consumption.
Semaglutide – Storage & Handling
Correct storage is essential for maintaining the stability and purity of Semaglutide. Follow the guidance below for both the lyophilised (freeze-dried) powder and any reconstituted solution.
- Store lyophilised powder at 2–8°C (refrigerated), protected from light
- For longer-term storage, keep frozen at -20°C in the original sealed vial
- Once reconstituted, refrigerate at 2–8°C and use within 30 days
- Avoid repeated freeze-thaw cycles once reconstituted
- Shelf life of 24 months from manufacture date when stored correctly
Semaglutide – Technical Specifications
Every batch of Semaglutide is independently analysed before dispatch. The values below describe the current research batch.
| Product Name | Semaglutide |
|---|---|
| CAS Number | 910463-68-2 |
| Molecular Formula | C₁₈₇H₂₉₁N₄₅O₅₉ |
| Molecular Weight | 4113.58 g/mol |
| Quantity / Strength | 5mg | 10mg | 20mg |
| Purity | ≥ 99% (HPLC) |
| Form | Lyophilised Powder |
| Appearance | White Lyophilised Powder |
| Batch Number | PA-0046 |
| Storage Conditions | 2°C-8°C (Refrigerated) |
| Category | Weight Loss |
| Intended Use | Research Use Only — not for human consumption |
Semaglutide – Certificate of Analysis
Every batch of Semaglutide is independently tested before dispatch. View the full COA for the current batch below.
Certificate of Analysis (COA)
Batch Number PA-0046
Research Disclaimer
This content is provided for educational, scientific and research-information purposes only. It does not provide medical advice, treatment recommendations or personal dosage instructions. Semaglutide has been investigated extensively in preclinical and clinical research, but the regulatory status, safety, efficacy and approved uses of registered semaglutide medicines should not be attributed to unregistered or research-grade products.
- Not for human or veterinary use
- No claims are made regarding safety or efficacy in humans
- Must be handled with appropriate laboratory safety equipment
- Purchaser assumes all responsibility for legal, compliant use
References
5 sources- 1Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016;375(19):1834-1844.PubMed: https://pubmed.ncbi.nlm.nih.gov/27633186/
- 2Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021;384(11):989-1002.PubMed: https://pubmed.ncbi.nlm.nih.gov/33567185/
- 3Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity, and Type 2 Diabetes (STEP 2): A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Phase 3 Trial. The Lancet. 2021;397(10278):971-984.PubMed: https://pubmed.ncbi.nlm.nih.gov/33667417/
- 4Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023;389(24):2221-2232.PubMed: https://pubmed.ncbi.nlm.nih.gov/37952131/
- 5Australian Government, Therapeutic Goods Administration (TGA). Compounding Safety Information: Semaglutide-Like Products. Therapeutic Goods Administration. 15 December 2023.TGA: https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/compounding-safety-information-semaglutide-products
Citations are provided for research reference and open in a new tab. Listing a study does not imply it evaluated this specific product.
Semaglutide – Frequently Asked Questions
Why Researchers Choose Us



